LATIFY De-Risking Map

NCT05450692

Ceralasertib (ATRi) + Durvalumab (PD-L1) // AZ Phase III NSCLC failure

8D Vector Failure Analysis
Trial Vector
Responder
Non-Responder
Alignment Zone

cosine = 0.9852

Vector Math
cos(θ) = (A·B) / (||A|| ||B||)
TARGET RESPONDER0.9852
ITT DILUTED0.6194
Observed HR0.90
Gate Evaluation
GATE 1: TARGET MATCHRANK #1 (POST STK11_SENSITIVE TAG)
PASS
GATE 2: COHORT EXCLUSIONRANK #129
PASS
GATE 3: PREDICTIVE EFFICACYΔ +0.3658
PASS
VERDICTFAILURE_PREDICTED
Observed HR
0.90Primary OS
P-Value
0.287Non-Sig
Engine Futility
90%Predicted
Stratification
MISSINGSTK11/KEAP1
Market Significance
Target Sub-Pop45,000–70,000 US / Yr
Annual Savings$4–7B Payer Value

Identifying non-responders before enrollment saves $150K per patient course.

System Summary
Database Scored2888 TRIALS
Prediction LayerTWO-LAYER AI
StatusFAILURE PREDICTED
Gates3/3 PASS